The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus

Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819.


The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a prophylactic HIV-1 vaccine. Here, we discuss the difficulties of achieving broad HIV-1 neutralization in the context of both the effective annual human influenza virus vaccine and the need to develop a pandemic influenza vaccine. Immunogen-design strategies are underway to target functionally conserved regions of the HIV-1 envelope glycoproteins, and similar strategies might be applicable to pandemic influenza virus vaccine development. Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / immunology*
  • Animals
  • Antibodies, Viral / blood*
  • Drug Design
  • HIV Antibodies / blood*
  • HIV Infections / immunology
  • HIV Infections / prevention & control
  • HIV-1 / immunology*
  • Humans
  • Influenza A virus / immunology
  • Influenza Vaccines / immunology*
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control
  • Neutralization Tests
  • Viral Envelope Proteins / immunology
  • env Gene Products, Human Immunodeficiency Virus / immunology


  • AIDS Vaccines
  • Antibodies, Viral
  • HIV Antibodies
  • Influenza Vaccines
  • Viral Envelope Proteins
  • env Gene Products, Human Immunodeficiency Virus